Export 1712 results:
Autore Titolo Tipo [ Anno(Asc)]
Filtri: First Letter Of Last Name è S  [Clear All Filters]
2012
Agostinis C, Bulla R, Tisato V, De Seta F, Alberico S, Secchiero P, Zauli G. Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells. Hum Reprod 2012;27(10):2941-7.
Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MGrazia, Lanza F, Secchiero P. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica 2012;97(11):1722-30.
Bernardi S, Secchiero P, Zauli G. State of art and recent developments of anti-cancer strategies based on TRAIL. Recent Pat Anticancer Drug Discov 2012;7(2):207-17.
Zauli G, Voltan R, Tisato V, Secchiero P. State of the art of the therapeutic perspective of sorafenib against hematological malignancies. Curr Med Chem 2012;19(28):4875-84.
Fulle S, Centurione L, Mancinelli R, Sancilio S, Manzoli FAntonio, Di Pietro R. Stem cell ageing and apoptosis. Curr Pharm Des 2012;18(13):1694-717.
Codrich D, Lembo MAntonietta, Schleef J. Thoracoscopic removal of a bulky cystic mediastinal mature teratoma in a 4-year-old child: report of one case and few surgical tricks. Eur J Pediatr Surg 2012;22(4):318-20.
Bernardi S, Zauli G, Tikellis C, Candido R, Fabris B, Secchiero P, Cooper ME, Thomas MC. TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) 2012;123(9):547-55.
Secchiero P, Zauli G. TRAIL, a new weapon against neointimal hyperplasia. Cardiology 2012;123(2):94-6.
Marcuzzi A, Secchiero P, Crovella S, Zauli G. TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyldipeptide or lipopolysaccharide. Cytokine 2012;60(1):43-6.
Bernardi S, Milani D, Fabris B, Secchiero P, Zauli G. TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases. Curr Drug Targets 2012;13(9):1215-21.
Toffoli B, Bernardi S, Candido R, Zacchigna S, Fabris B, Secchiero P. TRAIL shows potential cardioprotective activity. Invest New Drugs 2012;30(3):1257-60.
Tancini B, Magini A, Bortot B, Polchi A, Urbanelli L, Sonnino S, Severini GMaria, Emiliani C. Β-hexosaminidase over-expression affects lysosomal glycohydrolases expression and glycosphingolipid metabolism in mammalian cells. Mol Cell Biochem 2012;363(1-2):109-18.

Amministrazione Trasparente